StockData
ANGONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends May 31

ANGIODYNAMICS INC

Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 8, 2026
$11.39+0.15 (+1.33%)

Close on Oct 19, 2026

Market cap
$478.63M
P/E (TTM)
–
Dividend yield
–

About Angiodynamics

Surgical & Medical Instruments & Apparatus, SIC 3841

AngioDynamics designs, manufactures, and markets medical devices and technologies used to treat cardiovascular disease and cancer. The company operates through two main business segments: Med Tech and Med Device. Its product portfolio includes atherectomy systems, mechanical thrombectomy and venous drainage devices, thrombolytic catheters, irreversible electroporation and microwave tissue ablation platforms, angiographic catheters, guidewires, drainage catheters, micropuncture kits, and implantable ports. Its target customers and end users include interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses.

The company markets its products in the United States primarily through a direct sales team and internationally via direct sales and distributor arrangements across regions such as the European Union. AngioDynamics conducts manufacturing operations across two leased properties in Queensbury and Glens Falls, New York, while also utilizing third-party production facilities and leased distribution warehouses. The company maintains its corporate headquarters in Latham, New York.

Summary of the business section of Angiodynamics's latest annual report, written by StockData.

Company profile

Company

Legal name
ANGIODYNAMICS INC
Founded
1988
Headquarters
Latham, NY
Address
14 Plaza Drive 12110
Phone
(518) 798-1215
Employees
632, May 31, 2026
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
May 31
Auditor
Deloitte & Touche LLP, Boston, Massachusetts

Stock & identifiers

Ticker
ANGO
Exchange
Nasdaq
IPO date
May 27, 2004
Shares outstanding
42M, Sep 18, 2026
Public float
$436.29M, Nov 30, 2025
Filer category
Accelerated filer
SEC CIK
1275187
CUSIP
03475V101
ISIN
US03475V1017
LEI
549300W3VKC5ZKMO8C28
EIN
11-3146460

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
James C. ClemmerPresident and CEO, Director862,448
Warren Nighan JRSVP Quality and Regulatory64,745
Laura PiccininiSVP International81,929
Chad Thomas CampbellSVP/GM, Vascular Access111,006
Stephen A. TrowbridgeEVP and CFO314,115
Lawrence T. WeissSVP, Chief Legal Officer112,618
Lorinda BurgessDirector67,144
Eileen O'Shea AuenDirector116,605
Jan Stern ReedDirector116,921
Michael E. TarnoffDirector95,265
Wesley JohnsonDirector155,425
Karen A. LicitraDirector102,322
Howard W. DonnellyDirector178,938

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026
Mr. Clemmer
$6.06M$13.69M$1.80M$50$57
FY2025
Mr. Clemmer
$5.49M$6.81M$1.47M$44$43
FY2024
Mr. Clemmer
$5.01M$971.11K$1.26M$27$43
FY2023
Mr. Clemmer
$3.98M-$2.11M$914.24K$41$56
FY2022
Mr. Clemmer
$5.66M$4.95M$1.30M$85$59
FY2021
Mr. Clemmer
$4.05M$13.88M$1.03M$226$124

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Employees

Headcount reported in annual reports

“As of May 31, 2026, we had approximately 632 full time employees.”

Corporate history

Events identified from SEC filings